TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In the SIMPLIFIED trial, high-dose vitamin D3 did not significantly improve overall survival or several major health outcomes among 3,866 adults receiving dialysis. Researchers described possible benefits in some subgroups and cardiovascular measures as exploratory, not definitive.
A large U.K. trial found that high-dose vitamin D3 did not significantly improve overall survival among adults receiving dialysis for end-stage kidney disease. In the SIMPLIFIED trial, 3,866 participants assigned to vitamin D3 or standard care had no significant difference in survival over a median 7.5 years, according to results presented at the American Society of Nephrology Kidney Week meeting.
Participants were randomized to receive 60,000 IU of cholecalciferol every two weeks or standard care without the study supplementation. Researchers recorded 1,817 deaths during the trial. The primary analysis found a conditional hazard ratio of 0.95, with a 95% confidence interval of 0.86 to 1.04 and P=0.26, meaning the trial did not establish a survival benefit.
The researchers also reported no significant differences in secondary outcomes including fatal and nonfatal cardiovascular events, infections, fractures and cancer. Sensitivity analyses that accounted for kidney transplantation, COVID-19 infection and stopping treatment did not change the primary result. At least one hospital admission occurred in 69% of the vitamin D group and 70% of the standard-care group.
Vitamin D levels rose substantially in the treated group in an initial sample of 206 participants. After four months, median plasma 25-hydroxyvitamin D was 141 nmol/L in supplemented participants, compared with 36.5 nmol/L among controls. The trial report described high-dose cholecalciferol as safe and well tolerated, but raising vitamin D levels did not translate into a demonstrated overall survival advantage.
Routine High-Dose Treatment Not Supported
The findings address a practical question for patients on dialysis, a group facing high rates of illness and death. Vitamin D deficiency is common in this population, and observational studies have linked low levels with worse outcomes. But an association does not establish that supplementation prevents those outcomes. SIMPLIFIED tested a high-dose regimen directly and found no significant overall survival improvement.
Rona Smith, MD, of the University of Cambridge, said the findings “don’t support routine supplementation of high-dose cholecalciferol.” That conclusion applies to the trial regimen and population; it does not, by itself, resolve how clinicians should treat a patient who has a measured deficiency or another clinical reason for vitamin D replacement. Treatment decisions remain distinct from adopting high-dose supplementation for survival benefit.
The results also matter because they add randomized evidence in an area where prior evidence was limited. The finding may help patients and clinicians distinguish between correcting a deficiency under clinical guidance and taking a high dose in the hope of extending life. The trial did not show that vitamin D has no role in care; it did not demonstrate a survival benefit from the tested approach.
Products Worth Considering
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
Bowflex PR1000 Home Gym
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Navy
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Vitamin D
Guidance from Kidney Disease: Improving Global Outcomes recommends measuring 25-hydroxyvitamin D in people with stage 3-5 chronic kidney disease, including those on dialysis, and replacing it when levels are deficient. Smith said the guidelines acknowledge that the evidence grade is low. SIMPLIFIED was designed to address that evidence gap by testing supplementation against standard care.
The pragmatic study enrolled adults across 55 U.K. renal units. Participants had a median age of 65; 68% were men, 80% were white and 40% had diabetes. Nearly all received in-center hemodialysis, and the median time on dialysis was 2.25 years. Follow-up relied largely on routinely collected electronic health records after an in-person baseline assessment.
Smith described the population’s poor prognosis, saying that half of people who start dialysis will not be alive by five years and that cardiovascular disease accounts for most deaths. Earlier observational findings linking low vitamin D with adverse outcomes supplied a reason to test supplementation, but they could not establish that supplements would improve survival.
Subgroup Signals Need Testing
Prespecified subgroup analyses suggested a possible benefit among men and non-white participants. Smith cautioned that the trial was not powered to determine whether the treatment works in those groups, so the findings are hypothesis-generating rather than proof of a subgroup effect. She said lower baseline vitamin D levels among non-white participants made that group of interest for future research.
A nominal reduction was also reported in overall major adverse cardiovascular events, with a hazard ratio of 0.88 (95% CI 0.78-0.99; P=0.03). The result was driven mainly by fewer peripheral arterial disease events, for which the hazard ratio was 0.80 (95% CI 0.65-0.99; P=0.04). Smith said the study was not powered to confirm findings for these individual outcomes. The report does not establish whether these signals would hold in another trial.
The available report does not provide enough detail to assess how results might differ across specific dialysis settings or among patients selected for diagnosed vitamin D deficiency. The overall result remains the clearest finding: the tested high-dose regimen did not significantly improve survival in the trial population.
Further Trials Would Need Focus
The results support further research into the exploratory findings, particularly whether outcomes differ among non-white patients or men and whether the cardiovascular signal can be reproduced. Any such study would need to be designed and sized to test those questions directly, rather than treating subgroup observations from this trial as conclusive.
For now, the reported evidence does not support routine use of the tested high-dose vitamin D regimen to improve survival for people on dialysis. The trial does not replace clinical assessment of vitamin D deficiency or existing guidance on measuring and treating low levels. The report does not specify a next trial or a timetable for further results.
Key Questions
Did high-dose vitamin D improve survival in dialysis patients?
No significant improvement was found. In SIMPLIFIED, survival did not differ significantly between patients assigned 60,000 IU of cholecalciferol every two weeks and those receiving standard care.
How many people took part in the SIMPLIFIED trial?
The trial randomized 3,866 adults receiving dialysis at 55 U.K. renal units. Participants were followed for a median of 7.5 years.
Did the trial find any possible benefits?
Analyses suggested possible signals among men and non-white participants, as well as a nominal reduction in major cardiovascular events. The researchers said these results were not definitive because the trial was not powered to confirm them.
Does this mean dialysis patients should not take vitamin D?
The trial tested a particular high-dose regimen for survival benefit; it does not answer every question about vitamin D treatment. Kidney guidelines recommend measuring vitamin D levels in people with advanced chronic kidney disease and replacing it if deficient. Patients should discuss treatment with a qualified clinician.
Source: medpagetoday.com
